Carson Wealth (CWM LLC)
PRME icon

Carson Wealth (CWM LLC)’s Prime Medicine PRME Stock Holding History

Carson Wealth (CWM LLC)’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$118K Buy
33,811
+8,384
+33% +$31.9K ﹤0.01% 3122
2025
Q4 		$88K Buy
25,427
+75
+0.3% +$334 ﹤0.01% 3166
2025
Q3 		$140K Sell
25,352
-10,409
-29% -$42.3K ﹤0.01% 2723
2025
Q2 		$88K Buy
35,761
+15,295
+75% +$23.6K ﹤0.01% 2832
2025
Q1 		$41K Buy
20,466
+18,034
+742% +$46K ﹤0.01% 3145
2024
Q4 		$7K Buy
2,432
+2,410
+10,955% +$8.46K ﹤0.01% 4071
2024
Q3 		$0 Sell
22
-304
-93% -$1.41K ﹤0.01% 5077
2024
Q2 		$2K Buy
326
+276
+552% +$1.67K ﹤0.01% 4254
2024
Q1 		$0 Buy
50
+4
+9% +$30 ﹤0.01% 4659
2023
Q4 		$0 Buy
+46
New +$354 ﹤0.01% 4436
2023
Q3 		– Sell
-15
Closed – – 4464
2023
Q2 		$0 Hold
15
– – ﹤0.01% 4404
2023
Q1 		$0 Buy
+15
New +$244 ﹤0.01% 4282

Other funds holding PRME

Alphabet Inc
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Woodline Partners
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Carson Wealth (CWM LLC)'s PRME Position: Q1 2026 in Review

Carson Wealth (CWM LLC) increased its Prime Medicine (PRME) stake by 33% in Q1 2026, buying an estimated $31.9K and bringing the position to 33,811 shares worth $118K. The position accounts for ﹤0.01% of the portfolio, ranked #3122.

Carson Wealth (CWM LLC) first reported a position in PRME in Q1 2023 and has held it in 12 quarters since. The position peaked at $140K in Q3 2025. 192 funds tracked by Wall St. Rank hold PRME as of Q1 2026.

  • Carson Wealth (CWM LLC) held 33,811 shares of Prime Medicine worth $118K as of Q1 2026.
  • Carson Wealth (CWM LLC) bought 8,384 Prime Medicine shares in Q1 2026, an estimated $31.9K.
  • Prime Medicine made up ﹤0.01% of Carson Wealth (CWM LLC)'s portfolio in Q1 2026, its #3122 holding.
  • Carson Wealth (CWM LLC) first reported a position in Prime Medicine in Q1 2023 and has held it in 12 quarters since.
  • Carson Wealth (CWM LLC)'s Prime Medicine position peaked at $140K in Q3 2025.
  • 192 funds tracked by Wall St. Rank held Prime Medicine as of Q1 2026.

Based on Carson Wealth (CWM LLC)'s 13F filing for Q1 2026, filed 14 May 2026.